Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.26 Bil Enterprise Value: 13.31 Bil PE Ratio: 70.58 PB Ratio: 2.82 GF Score: 62/100

Biomarin Pharmaceutical Inc at Leerink Global Healthcare Conference Transcript

Feb 26, 2020 / 03:00PM GMT
Joseph Patrick Schwartz
SVB Leerink LLC, Research Division - MD of Rare Diseases & Senior Research Analyst

Okay. Good morning. I'm Joe Schwartz from the SVB Leerink equity research biopharma team. It's my pleasure to host this fireside chat with Geoff Nichol, Senior Vice President, CMO and Head of Clinical Development at BioMarin. And we have a lot to talk about, so -- and a very exciting time for the company.

Why don't we just start by having you give us a quick lay of the land on your various programs and their status, and then we'll dive into Q&A?

Geoffrey M. Nichol
BioMarin Pharmaceutical Inc. - Senior VP, Chief Medical Officer & Head of Global Clinical Development

Okay. Great. Well, certainly, I'll show a few slides. But I've been at BioMarin 3 and a bit years, and it's been a time of just -- for someone who's into late-stage clinical development like me, it's been -- I've been like a pig in the proverbial because it's been incredibly busy. We've had an enormous amount of success. And this is a time for BioMarin where the company is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot